What Happened
- The Drugs Controller General of India (DCGI) conducted inspections and audits at 49 entities — including online pharmacy warehouses, drug wholesalers, retailers, wellness clinics, and slimming centres — to check for unauthorised sale and promotion of GLP-1 receptor agonist weight-loss drugs.
- Inspections revealed significant violations: drugs sold without valid prescriptions, inadequate medical oversight, and surrogate advertising that indirectly promoted the drugs to avoid direct-to-consumer restrictions.
- On March 10, 2026, the DCGI issued a comprehensive advisory prohibiting surrogate advertisements and any form of indirect promotion of GLP-1 drugs.
- The regulatory crackdown followed explosive market growth: GLP-1 injectable segment sales rose 177% (moving annual turnover basis) to ₹1,446 crore in February 2026 from ₹571 crore in February 2025.
- Indian pharma companies launched over 15 generic versions of GLP-1 agonists within two days of the molecule losing patent protection, causing a 50–70% price drop — dramatically expanding access and potential for misuse.
Static Topic Bridges
GLP-1 Receptor Agonists — Mechanism and Drug Class
Glucagon-Like Peptide-1 (GLP-1) receptor agonists are a class of drugs originally developed for Type 2 diabetes that have gained major attention for weight management. GLP-1 is a natural incretin hormone secreted by intestinal L-cells after food intake; it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on the hypothalamus to reduce appetite. Synthetic GLP-1 receptor agonists mimic this hormone, producing sustained appetite suppression and significant weight loss (15–20% body weight in clinical trials).
- Original indication: Type 2 diabetes mellitus (approved in India as anti-diabetic drugs)
- Weight loss indication: Semaglutide (brand: Ozempic for diabetes, Wegovy for obesity) and Liraglutide (Saxenda) are globally approved for chronic weight management
- Mechanism: Binds GLP-1 receptors in the pancreas, gut, and brain — reduces appetite via hypothalamic signalling
- Common side effects: Nausea, vomiting, pancreatitis risk, thyroid C-cell tumour risk (in animal studies)
- In India, GLP-1 drugs are approved primarily as anti-diabetic agents; their use for weight loss alone is largely off-label
- Generic semaglutide entered the Indian market after patent expiry, causing the price crash that drove the demand surge
Connection to this news: The mass adoption of GLP-1 drugs for weight loss — including off-label use, sale without prescription, and aggressive marketing — triggered the DCGI crackdown, as these drugs carry significant cardiovascular, gastrointestinal, and endocrine side-effect profiles requiring medical supervision.
Drugs and Cosmetics Act, 1940 — Regulatory Framework for Prescription Drugs
The Drugs and Cosmetics Act, 1940 is the primary legislation governing manufacture, distribution, and sale of drugs in India. Under this Act and the Drugs and Cosmetics Rules, 1945, drugs are classified as Schedule H or Schedule H1 (prescription-only drugs requiring a doctor's prescription for dispensing). Section 26A empowers the Central Government to ban or restrict manufacture, sale, or distribution of drugs that pose risk to human health or lack therapeutic justification.
- Schedule H drugs: Require a doctor's prescription; cannot be sold over the counter; pharmacist must retain a copy of the prescription
- Schedule H1: A higher category — includes drugs with abuse potential and serious side effects; pharmacist must record details in a register (Rule 65(15A))
- Section 26A: Central government power to prohibit manufacture, sale, or distribution of drugs in public interest — used extensively to ban irrational Fixed Dose Combinations (FDCs)
- CDSCO (Central Drugs Standard Control Organisation) under DGHS, MoHFW: National Regulatory Authority; headed by DCGI (Drugs Controller General of India)
- State Licensing Authorities (SLAs): Grant manufacturing and retail licences at the state level — creating a regulatory gap between central approval and state-level enforcement
- Advertisement of prescription drugs to the general public is prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
Connection to this news: GLP-1 drugs are Schedule H prescription drugs in India — their sale without prescriptions and surrogate advertising directly violates the Drugs and Cosmetics Act and the Advertisement Act, making the DCGI's enforcement actions legally grounded.
Drug Pricing and Patent Expiry — Generic Market Dynamics
India's pharmaceutical regulatory framework includes the Drug Price Control Order (DPCO) under the Essential Commodities Act, 1955, administered by the National Pharmaceutical Pricing Authority (NPPA). While GLP-1 drugs are not currently on the National List of Essential Medicines (NLEM), patent expiry of branded molecules (like semaglutide) triggers generic competition under the Patents Act, 1970 (as amended). India's compulsory licensing provisions (Section 84) and its historical position in the Doha Declaration on TRIPS allow India to prioritise public health over patent protection.
- NPPA: Regulates prices of drugs on the NLEM; drugs outside NLEM can have price increases capped at 10% annually under DPCO 2013
- NLEM 2022: The current national essential medicines list — GLP-1 drugs are not included
- Generic manufacturers can produce patent-expired molecules; price competition after patent expiry is intended to improve access (the 177% sales growth reflects this democratisation of access)
- The challenge: Rapid price drops and generic availability without a matching increase in medical supervision infrastructure creates "pharmacy-shop medicine" culture for complex drugs
Connection to this news: The 50–70% price drop following generic entry made GLP-1 drugs affordable to a much larger population, but without adequate prescription controls, this created the access-without-supervision problem the DCGI is now addressing.
Key Facts & Data
- GLP-1 injectable segment sales (Feb 2026): ₹1,446 crore (up 177% from ₹571 crore in Feb 2025)
- Generic versions launched after patent expiry: 15+ Indian manufacturers within two days
- Price drop post-generic entry: 50–70% compared to innovator drug prices
- Inspections conducted: 49 entities (online pharmacies, wholesalers, retailers, wellness clinics)
- DCGI advisory against surrogate ads: March 10, 2026
- Regulatory action on non-compliance: cancellation of drug licences, penalties, prosecution under Drugs and Cosmetics Act, 1940
- Schedule H drugs require written prescription; Schedule H1 requires pharmacist register entry
- Section 26A of Drugs and Cosmetics Act, 1940: Central government power to ban drugs in public interest